Highlights

  • Hydralyte USA has secured firm commitments to raise A$392,000 through a placement.
  • The company will issue 98 million new shares at A$0.004 per share.
  • A further 49 million options are proposed, subject to shareholder approval.
  • The Board and management team have undergone significant changes, including the appointment of two new Non-Executive Directors.
  • Annual cash expenses are expected to reduce by approximately A$500,000 following cost reduction initiatives.
  • Management continues to focus on US sales growth, operational efficiencies and strategic acquisition opportunities.

Hydration Pharmaceuticals Co Ltd (ASX:HPC), trading as Hydralyte USA, has announced a capital raising, board renewal and management restructuring as the company seeks to strengthen its financial position and support its ongoing US operations.

The company has secured firm commitments to raise A$392,000 through a placement to investor George Karafotios. Alongside the funding initiative, Hydralyte has introduced changes to its Board and executive structure while outlining a cost reduction program aimed at improving operating cash flow.

Hydralyte USA shares closed unchanged at AUD 0.004 on 15 June 2026. The company's latest announcement focused on capital management, operational efficiencies and leadership changes as it continues pursuing growth opportunities within its US business.

About Hydralyte USA

Hydralyte USA is focused on hydration solutions and operates primarily in the United States market.

The company continues to develop its sales strategy through established e-commerce channels and traditional retail distribution, with a focus on high-margin products.

Management's current priorities include improving operating performance, supporting sales momentum, strengthening the balance sheet and exploring opportunities that may add scale to the business.

The latest announcement forms part of these broader objectives, combining fresh capital, cost-saving measures and leadership changes designed to support future operations.

Placement Raises A$392,000

The centrepiece of the announcement was a placement expected to raise A$392,000 before costs.

Under the agreement, Hydralyte will issue 98 million new fully paid ordinary shares at A$0.004 per share to George Karafotios or his nominee.

The company stated that the placement price represents no premium to the closing share price on 11 June 2026 and approximately a 3% premium to the 15-day volume-weighted average price up to and including 12 June 2026.

The shares will be issued using the company's existing placement capacity under ASX Listing Rules 7.1 and 7.1A.

Completion of the placement is expected on 17 June 2026.

According to management, the funds will primarily support sales momentum in the US market while also contributing to working capital requirements.

Proposed Options Add Additional Capital Potential

In addition to the placement shares, Hydralyte plans to issue 49 million options on a one-for-two basis relative to the shares issued under the placement.

The proposed options will carry an exercise price of A$0.006 per option and will have a term of three years from the issue date.

The exercise price represents a 50% premium to the placement price.

The issue of the options remains subject to shareholder approval.

If exercised in the future, the options could provide an additional source of capital for the company, although no assumptions have been made regarding future exercises.

Board Undergoes Significant Renewal

Hydralyte also announced several Board changes as part of its governance refresh.

George Karafotios and Nick Katiforis have been appointed as Non-Executive Directors, effective from 16 June 2026 following completion of the placement.

The company stated that the new appointments are intended to strengthen the Board as it focuses on achieving a pathway toward cash-flow breakeven from continuing US operations.

At the same time, Adem Karafili resigned as Non-Executive Chair and Joseph Constable resigned as Non-Executive Director.

Following these changes, Nick Berry will assume the role of Non-Executive Chair.

Management indicated that the combined experience of the newly appointed directors is expected to support the company's growth strategy and evaluation of strategic opportunities.

New Directors Bring Capital Markets and Restructuring Experience

Hydralyte highlighted the professional backgrounds of its incoming directors.

George Karafotios has experience in restructuring, turnaround strategies and executive leadership roles within ASX-listed companies. He holds a Bachelor of Commerce degree from the University of Adelaide.

Nick Katiforis brings more than two decades of experience across financial services, capital markets, equities, options and foreign exchange markets.

He has served as a Director of Futurity Trading since 2000 and holds ASIC financial adviser accreditation.

The company believes these skills will complement the existing Board as it pursues growth initiatives and strategic opportunities.

CEO Resigns as Operational Structure Changes

The company also confirmed that Chief Executive Officer Oliver Baker resigned from his position effective 15 June 2026.

Hydralyte acknowledged Mr Baker's contribution to the company and confirmed he will remain involved through consultancy arrangements to assist with the transition.

To support operational continuity, current e-commerce lead Emily Lease has been appointed General Manager.

She will oversee day-to-day operations and commercial execution across all business channels.

According to the company, Ms Lease will be supported by the existing fractional Chief Financial Officer and by Mr Baker in a consultancy capacity when required.

Management stated that the revised structure is intended to provide continuity while supporting operational efficiency.

Cost Reduction Program Targets Annual Savings

A key element of the announcement was the company's focus on reducing operating expenses.

Hydralyte advised that Board remuneration will be reduced significantly as part of the cost management program.

Annual Non-Executive Director fees will be reduced to A$40,000 per director, resulting in a reduction in Board remuneration from approximately A$243,000 to A$120,000 per annum.

Combined with lower wage costs following the CEO transition and other expense reductions, management expects overall annual cash expenses to decline by approximately A$500,000.

The company expects these savings to begin flowing through from mid-June 2026.

The reduction in expenditure forms part of the company's broader objective of improving cash flow performance.

Focus Remains on US Sales Momentum

Hydralyte indicated that proceeds from the placement will support continuing sales momentum across its US operations.

The company noted that recent growth trends through established e-commerce channels remain a focus area.

Management is seeking to consolidate these trends while maintaining operational discipline through a streamlined cost base.

The company continues to target a pathway toward cash-flow breakeven through a combination of revenue growth and cost reductions.

Its focus remains on online and traditional retail sales of higher-margin products within the US market.

Outlook Points to Improved Operating Cash Flow

Looking ahead, management expects previous sales disruptions experienced in earlier quarters to continue normalising.

The company stated that inventory levels have improved heading into the peak US summer trading period.

Hydralyte believes the combination of stronger inventory availability and planned cost reductions should contribute to further improvement in operating cash flow performance.

Management indicated that these benefits are expected to become more visible from the third quarter of FY26.

The company did not provide formal earnings guidance but highlighted operating cash flow improvement as a key objective.

Strategic M&A Opportunities Remain Under Review

Alongside operational initiatives, Hydralyte continues evaluating strategic opportunities that may strengthen the business.

Management stated that the company is exploring opportunities to add scale to its existing platform and further enhance the balance sheet.

Potential merger and acquisition opportunities remain part of the company's broader strategic agenda.

The Board believes the new funding, revised leadership structure and strengthened financial flexibility provide greater scope to assess opportunities that may create shareholder value.

No specific transactions were disclosed in the announcement.

What This Means for Investors

Hydralyte USA's latest update combines capital raising, leadership changes and cost management initiatives aimed at supporting its US operations.

The A$392,000 placement strengthens liquidity, while the appointment of new directors and operational restructuring introduce a refreshed governance and management framework. At the same time, annual cash expense reductions of approximately A$500,000 are expected to improve the company's cost profile.

Investors are likely to monitor the completion of the placement, implementation of the cost reduction program, operating cash flow performance during FY26 and any future developments relating to strategic acquisition opportunities.